Literature DB >> 27783944

An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.

Vivekananda Kedage1, Nagarathinam Selvaraj2, Taylor R Nicholas3, Justin A Budka2, Joshua P Plotnik3, Travis J Jerde4, Peter C Hollenhorst5.   

Abstract

More than 50% of prostate tumors have a chromosomal rearrangement resulting in aberrant expression of an oncogenic ETS family transcription factor. However, mechanisms that differentiate the function of oncogenic ETS factors expressed in prostate tumors from non-oncogenic ETS factors expressed in normal prostate are unknown. Here, we find that four oncogenic ETS (ERG, ETV1, ETV4, and ETV5), and no other ETS, interact with the Ewing's sarcoma breakpoint protein, EWS. This EWS interaction was necessary and sufficient for oncogenic ETS functions including gene activation, cell migration, clonogenic survival, and transformation. Significantly, the EWS interacting region of ERG has no homology with that of ETV1, ETV4, and ETV5. Therefore, this finding may explain how divergent ETS factors have a common oncogenic function. Strikingly, EWS is fused to various ETS factors by the chromosome translocations that cause Ewing's sarcoma. Therefore, these findings link oncogenic ETS function in both prostate cancer and Ewing's sarcoma.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ERG; ETS; EWS; Ewing’s sarcoma; prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 27783944      PMCID: PMC5123826          DOI: 10.1016/j.celrep.2016.10.001

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  52 in total

Review 1.  Biology of EWS/ETS fusions in Ewing's family tumors.

Authors:  A Arvand; C T Denny
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

2.  Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells.

Authors:  Peter C Hollenhorst; Mary W Ferris; Megan A Hull; Heejoon Chae; Sun Kim; Barbara J Graves
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

3.  FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.

Authors:  Paula Paulo; João D Barros-Silva; Franclim R Ribeiro; João Ramalho-Carvalho; Carmen Jerónimo; Rui Henrique; Guro E Lind; Rolf I Skotheim; Ragnhild A Lothe; Manuel R Teixeira
Journal:  Genes Chromosomes Cancer       Date:  2011-11-12       Impact factor: 5.006

4.  EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing.

Authors:  L Yang; H A Chansky; D D Hickstein
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

5.  Promotion and maintenance of leukemia by ERG.

Authors:  Shinobu Tsuzuki; Osamu Taguchi; Masao Seto
Journal:  Blood       Date:  2011-02-14       Impact factor: 22.113

6.  Stimulation of Oct-4 activity by Ewing's sarcoma protein.

Authors:  Jungwoon Lee; Byung Kirl Rhee; Gab-Yong Bae; Yong-Mahn Han; Jungho Kim
Journal:  Stem Cells       Date:  2005 Jun-Jul       Impact factor: 6.277

7.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Authors:  Brett S Carver; Jennifer Tran; Anuradha Gopalan; Zhenbang Chen; Safa Shaikh; Arkaitz Carracedo; Andrea Alimonti; Caterina Nardella; Shohreh Varmeh; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

8.  ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.

Authors:  Ping Chi; Yu Chen; Lei Zhang; Xingyi Guo; John Wongvipat; Tambudzai Shamu; Jonathan A Fletcher; Scott Dewell; Robert G Maki; Deyou Zheng; Cristina R Antonescu; C David Allis; Charles L Sawyers
Journal:  Nature       Date:  2010-10-03       Impact factor: 49.962

9.  Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells.

Authors:  Nagarathinam Selvaraj; Vivekananda Kedage; Peter C Hollenhorst
Journal:  Cell Commun Signal       Date:  2015-02-19       Impact factor: 5.712

10.  ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells.

Authors:  Joshua P Plotnik; Justin A Budka; Mary W Ferris; Peter C Hollenhorst
Journal:  Nucleic Acids Res       Date:  2014-10-07       Impact factor: 16.971

View more
  16 in total

1.  Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation.

Authors:  Vivekananda Kedage; Brady G Strittmatter; Paige B Dausinas; Peter C Hollenhorst
Journal:  J Biol Chem       Date:  2017-09-08       Impact factor: 5.157

2.  ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming.

Authors:  Fei Li; Qiuyue Yuan; Wei Di; Xinyi Xia; Zhuang Liu; Ninghui Mao; Lin Li; Chunfeng Li; Juan He; Yunguang Li; Wangxin Guo; Xiaoyu Zhang; Yiqin Zhu; Rebiguli Aji; Shangqian Wang; Xinyuan Tong; Hongbin Ji; Ping Chi; Brett Carver; Yong Wang; Yu Chen; Dong Gao
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

3.  FUS-mediated regulation of acetylcholine receptor transcription at neuromuscular junctions is compromised in amyotrophic lateral sclerosis.

Authors:  Gina Picchiarelli; Maria Demestre; Amila Zuko; Marije Been; Julia Higelin; Stéphane Dieterlé; Marc-Antoine Goy; Moushami Mallik; Chantal Sellier; Jelena Scekic-Zahirovic; Li Zhang; Angela Rosenbohm; Céline Sijlmans; Amr Aly; Sina Mersmann; Inmaculada Sanjuan-Ruiz; Annemarie Hübers; Nadia Messaddeq; Marina Wagner; Nick van Bakel; Anne-Laurence Boutillier; Albert Ludolph; Clotilde Lagier-Tourenne; Tobias M Boeckers; Luc Dupuis; Erik Storkebaum
Journal:  Nat Neurosci       Date:  2019-10-07       Impact factor: 24.884

4.  Slow skeletal muscle troponin T, titin and myosin light chain 3 are candidate prognostic biomarkers for Ewing's sarcoma.

Authors:  Yajun Deng; Qiqi Xie; Guangzhi Zhang; Shaoping Li; Zuolong Wu; Zhanjun Ma; Xuegang He; Yicheng Gao; Yonggang Wang; Xuewen Kang; Jing Wang
Journal:  Oncol Lett       Date:  2019-11-04       Impact factor: 2.967

Review 5.  Ras and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis.

Authors:  Shian-Ren Lin; Ntlotlang Mokgautsi; Yen-Nien Liu
Journal:  Molecules       Date:  2020-05-20       Impact factor: 4.411

6.  Toll-like receptor 4 signaling activates ERG function in prostate cancer and provides a therapeutic target.

Authors:  Benjamin M Greulich; Joshua P Plotnik; Travis J Jerde; Peter C Hollenhorst
Journal:  NAR Cancer       Date:  2021-01-27

7.  Genomic and transcriptomic characterization of the human glioblastoma cell line AHOL1.

Authors:  W A S Ferreira; C K N Amorim; R R Burbano; R A R Villacis; F A Marchi; T S Medina; M M C de Lima; E H C de Oliveira
Journal:  Braz J Med Biol Res       Date:  2021-01-15       Impact factor: 2.590

8.  Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.

Authors:  Gabriel J Sandoval; John L Pulice; Hubert Pakula; Monica Schenone; David Y Takeda; Marius Pop; Gaylor Boulay; Kaylyn E Williamson; Matthew J McBride; Joshua Pan; Roodolph St Pierre; Emily Hartman; Levi A Garraway; Steven A Carr; Miguel N Rivera; Zhe Li; Lucienne Ronco; William C Hahn; Cigall Kadoch
Journal:  Mol Cell       Date:  2018-08-02       Impact factor: 19.328

9.  Identification of potential functional genes in papillary thyroid cancer by co-expression network analysis.

Authors:  Zeng-Xin Ao; Yuan-Cheng Chen; Jun-Min Lu; Jie Shen; Lin-Ping Peng; Xu Lin; Cheng Peng; Chun-Ping Zeng; Xia-Fang Wang; Rou Zhou; Zhi Chen; Hong-Mei Xiao; Hong-Wen Deng
Journal:  Oncol Lett       Date:  2018-08-14       Impact factor: 2.967

10.  --A high-throughput screen identifies inhibitors of the interaction between the oncogenic transcription factor ERG and the cofactor EWS.

Authors:  Taylor R Nicholas; Jingwei Meng; Benjamin M Greulich; Teresa Stevie Morris; Peter C Hollenhorst
Journal:  PLoS One       Date:  2020-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.